Intravitreal triamcinolone inhibits choroidal neovascularization. To investigate if vascular endothelial growth factor (VEGF) is affected, we examined VEGF expression after intravitreal triamcinolone administration in rat retina. Using in situ hybridization, we have found dense clustered VEGF mRNA signals in the retinal pigment epithelium, moderate patchy signals in the inner nuclear layer, and positive labeling in a sub-population of ganglion cells. Densitometry and northern blot analysis revealed no significant alteration of VEGF mRNA expression pattern and level 3-21 days after triamcinolone injection. Our data indicate that intravitreal triamcinolone does not affect basal VEGF mRNA expression in normal adult rat retina.
Introduction
Sub-retinal choroidal neovascularization (CNV) in the macula is responsible for the majority of severe vision loss due to age-related macular degeneration (AMD). Traditional argon or krypton laser photocoagulation was proven beneficial in the Macular Photocoagulation Study (Macular Photocoagulation Study Group, 1991) , but is limited to classic CNV and currently used for treatment of parafoveal classic CNV. Photodynamic therapy (PDT), recently approved for exudative AMD, is now a popular treatment for subfoveal or juxtafoveal CNV and has proven beneficial for approximately 60%-70% CNV patients (Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group, 1999 Group, , 2001 ). However, its limitations are that majority of patients needs multiple treatments, that it is not effective for some patients and only approved for lesions with more than 50% classic CNV. Triamcinolone has long been used as an intravitreal anti-angiogenesis agent in animal models. Tano et al. first observed that intravitreal triamcinolone acetonide significantly reduced retinal neovascularization and fibrosis caused by autotransplanted fibroblasts in rabbit (Tano, Chandler, & Machemer, 1980) . This was later confirmed by other studies (Antoszyk, Gottlieb, Machemer, & Hatchell, 1993) . Intravitreal triamcinolone inhibited retinal neovascularization in animal models of branch retinal vein occlusion (Danis, Bingaman, Yang, & Ladd, 1996) . Penfold, Gyory, Hunyor, and Billson (1995) first employed intravitreal triamcinolone on human exudative AMD patients and found that it significantly reduced severe vision loss, and stabilized CNV membrane on fluorescein angiogram. This clinical study was subsequently confirmed and supplemented by other studies (Challa et al., 1998; Danis, Ciulla, Pratt, & Anliker, 2000) . A recent study showed that intravitreal triamcinolone stabilized recurrent CNV in patients with prior laser treatments (Ranson, Danis, Ciulla, & Pratt, 2002) . Intravitreal triamcinolone also inhibits development of sub-retinal neovascularization induced by laser treatment in rat models (Ciulla, Criswell, Danis, & Hill, 2001) . Although these studies showed that triamcinolone inhibited retinal and CNV, its mechanisms of anti-angiogenesis remain unknown.
It has been well known that vascular endothelial growth factor (VEGF) is an important angiogenesis factor in proliferative diabetic retinopathy Aiello et al., 1994; Malecaze et al., 1994) , in animal models of retinal hypoxia (Pierce, Avery, Foley, Aiello, & Smith, 1995) , and in retinal vein occlusion . Transgenic mice with VEGF overexpression showed significant pre-retinal and intraretinal neovascularization (Okamoto et al., 1997) . Neutralizing VEGF antibody or VEGF antisense oligodeoxynucleotides (Robinson et al., 1996) reduced retinal neovascularization significantly in animal models. Thus VEGF plays a central role in the development of retinal neovascularization due to retinal ischemia.
Despite extensive studies, the role of VEGF in the development of sub-retinal CNV is not as certain as that in the retinal neovascularization. Evidence has been accumulated that VEGF expression is increased in CNV membranes in human exudative AMD patients (Frank, 1997 (Frank, , 1999 and in animal models induced by laser treatment (Yi et al., 1997) . Sub-retinal implantation of VEGF-impregnated microspheres in monkey lead to the development of CNV similar to those seen in humans (Cui et al., 2000) . By blocking phosphorylation of VEGF receptor in laser induced mouse CNV model, Kwak et al. demonstrated that VEGF was a major stimulator of CNV development (Kwak, Okamoto, Wood, & Campochiaro, 2000) . Intravitreal anti-VEGF monoclonal antibody prevented CNV formation induced by laser treatment in monkey (Krzystolik et al., 2002) . Thus, VEGF appears to play a critical role in the development of CNV in human exudative AMD and in animal models induced by laser treatment.
It is evident that intravitreal triamcinolone can suppress or inhibit CNV, and that VEGF is a major stimulator of CNV, we ask the question whether triamcinolone elicits its inhibitory action of CNV development through inhibiting VEGF expression. As the first step to answer this question, we examined VEGF expression in a normal adult rat model following intravitreal triamcinolone treatment.
Materials and methods

Animals
Sprague-Dawley albino rats 6-7 weeks old (approximately 250 g) were obtained from Charles River Laboratories (Wilmington, MA). Animals were fed ab libitum with Purina lab chow and water with room lighting consisting of a 12 h light: 12 h dark cycle.
Triamcinolone intravitreal injection
Animals were anesthetized with intraperitoneal injections of Phenobarbital (Nembutal) (75 mg/kg). Proparacaine hydrochloride of 0.5% (Alcon Labs, Inc., Forth Worth, TX) was used for additional topical anesthesia. Ofloxacin ophthalmic solution of 0.3% (Allergan Inc, Irvene, CA) was applied to the ocular surface before injection, and bacitracin ophthalmic ointment of 500 units/g (E. Fougera & Co., Melville, NY) after injection, to prevent infection. Triamcinolone acetonide (40 mg/ml) was obtained from Greenpark Compounding Pharmacy (Houston, TX). A single dose of 320 lg in a volume of 8 ll was injected into the vitreous under a dissecting microscope using a Hamilton micro-injector (Hamilton Co. Reno, Nevada). A 30 gauge needle was first used to make a punch incision 0.5 mm posterior to the temporal limbus, and the Hamilton needle was then inserted through the incision, approximately 1.5 mm deep, angled towards the optic nerve until the tip of needle was seen in the center of vitreous. Intravitreal drug delivery was confirmed by observing white triamcinolone suspension in the posterior vitreous under the microscope. Eyes with lens injury from injection were excluded from the study. Since rat vitreous volume is 56 ll (Berkowitz, Lukaszew, Mullins, & Penn, 1998) , 320 lg of triamcinolone makes the final intravitreal concentration of 5.7 mg/ml. The dosage used on rats in this study is more than fivefold higher than that of 1 mg/ml used in human patients clinically (4 mg triamcinolone in 4 ml human vitreous volume). This high dose was chosen because the pharmacokinetics of the drug in the rat vitreous was unknown and because insufficient dosing was to be avoided. Balanced salt solution (BSS) (Alcon Labs, Inc., Forth Worth, TX) of 8 ll was used as a control and injected into the fellow eye of each animal. Animals were sacrificed at three days (N ¼ 3), one week (N ¼ 5), and two weeks (N ¼ 5) following injection and processed for in situ hybridization. For Northern blot analysis, 16 rats were treated with intravitreal triamcinolone and the fellow eye of each animal with BSS. Animals were sacrificed three weeks after injection, and the retinas were dissected for RNA isolation (see below).
Tissue preparation
Animals were euthanized with an overdose of phenobarbital. The eyes were enucleated, an incision was made in the cornea, and eyes were fixed immediately in 4% formaldehyde in 0.1 M phosphate buffer (pH 7.4). After 15 min in the fixative, lenses were removed and eyes were cut along the cornea-optic nerve axis into halves. Tissues were further fixed overnight in 4% paraformaldehyde and 0.5% glutaraldehyde in 0.1 M phosphate buffer (pH 7.4). Tissues were embedded in paraffin and sectioned at a thickness of 6 lm. The triamcinolone and BSS injected eye tissue sections from each animal were mounted on the same slide and processed identically so that sections could be directly compared with as little processing variability as possible.
In situ hybridization
Standard protocols of riboprobe in situ hybridization were followed as described in detail previously (Gao, Qiao, Hefti, Hollyfield, & Knusel, 1997; Qiao, Hefti, Knusel, & Noebels, 1996) . Rat VEGF cDNA clone was obtained as a generous gift from Dr. Salman Hyder at the University of Texas in Houston. It consists of 570 bases of coding region and was inserted into plasmid pBluecript SK (Hyder et al., 2000) . For generation of antisense VEGF riboprobes, the plasmid was linearized with restriction enzyme BamH1.
35 S-labeled antisense riboprobes were transcribed using T7 polymerase and Riboprobe Gemini System according to manufacturer's instructions (Promega Inc., Madison, WI). The tissue sections were deparaffinized in xylene followed by rehydration. The sections were first pretreated with 10 lg/ ml proteinase K at 37°C for 20 min, 0.25% acetic anhydrite and 0.1 M triethanolamide for 10 min. The tissue sections were then incubated at 50°C on a slide warmer for 18 ± 2 h with the probe solutions containing 5 · 10 6 cpm/ml 35 S-labeled probes, 50% formamide, 10% dextran sulfate, 300 mM NaCl, 0.5 mg/ml tRNA, 10 lM DTT, 0.02% Ficoll, 0.02% polyvinyl-pyrolidone, 0.02% BSA, and 1 mM EDTA in 10 mM Tris-HCl (pH 8.0). Following hybridization, the slides were rinsed in 4 · SSC (SSC: 150 mM NaCl and 15 mM sodium citrate), digested with 20 lg/ml RNase A at 37°C for 30 min, washed through descending concentrations of SSC to 0.1 · SSC at 60-70°C. The slides were then dehydrated in ethanol, dried and coated with NTB-2 liquid emulsion (Kodak Inc., Rochester, NY). Following exposure in the dark for four weeks, the emulsion was developed and sections were counter-stained with hematoxylin.
Image quantification
To quantitate and compare VEGF mRNA signals in retinal cells, image analysis was performed using computer enhanced video densitometry (Southern Micro Instruments, Atlanta, GA). VEGF mRNA positive cells were defined as those cells over which silver grains exceed five times the background value. Silver grain densities in the RPE, INL and ganglion cell layers were determined separately and compared between the triamcinolone and BSS control groups. For each group, three eyes were included with three tissue sections examined for each eye, and three window areas were analyzed in each section. A student t-test was used for statistical analysis between the two groups.
Northern blot
Three weeks after intravitreal injection of triamcinolone and of BSS in the fellow eye of each animal, 16 rats were sacrificed. There were still small amounts of white triamcinolone precipitates in the vitreous when eyes were enucleated. The retinas were dissected out and pooled, and total retinal RNA was isolated as described previously (Gao & Hollyfield, 1995) . The antisense VEGF riboprobe was synthesized as described above labeling with 32 P-CTP. Northern blot was performed using standard methods: the total RNA of 30 lg was separated on 1% agarose formaldehyde-denaturing gel. For one week group, 10 lg RNA was used. The RNA was blotted to 0.2 lm neutral nylon membranes (Schleicher & Schuell, Keene, NH) and hybridized to 32 P-labeled VEGF probe (3 · 10 6 cpm/ml). The membrane was then washed in graded SSC, dried, and exposed to PhosphorImager plate (Molecular Dynamics, Eugene, OR). Relative abundance of mRNA was quantified by reading the plate. VEGF mRNA signals at 4.2 kb were used to perform the densitometry. b-actin mRNA was also examined and used as an internal control. The same blot was re-probed and hybridized to 32 P-labeled b-actin probe. The ratio of VEGF/b-actin densities was then used for comparison between the triamcinolone and BSS control groups. Northern analysis was repeated three times, and t-test was used for statistical analysis.
Results
VEGF mRNA expression pattern in rat retina
Using radio-labeled rat VEGF riboprobes, in situ hybridization was performed on animal eyes three days, one week, and two weeks following intravitreal triamcinolone injection. As shown in Fig. 1 , VEGF mRNA expression signals are localized in the retinal pigment epithelium (RPE), cells in the inner nuclear layer (INL), and some ganglion cells. VEGF mRNA signal intensity is the highest in the RPE. Nearly every RPE cell is positive for VEGF mRNA signals, with clustered signals in each RPE cell around the nuclei. In the INL, VEGF signals appear patchy over cells, less clustered than in the RPE, and the signals are not as intense as in the RPE. VEGF signals in the ganglion cells are at moderate level, and only a sub-population of ganglion cells is positive for VEGF. Following intravitreal triamcinolone injection (Fig. 1B-D) , VEGF mRNA expression signals are very comparable with those in control eye injected with BSS (Fig. 1A ) in all layers: the RPE, INL and ganglion cells. Image analysis using densitometry to compare signal intensity in each layer between the triamcinolone and saline group retinas was performed and showed no statistically significant difference (p > 0:05) in signal intensity between them (Fig. 2) . There was also no difference of signal intensity among three days, one week and two week triamcinolone groups in any cell layers. Thus, triamcinolone does not change VEGF mRNA expression from three days to two weeks after intravitreal injection. To obtain a baseline VEGF mRNA expression in retina, normal adult rat retina without any intervention was examined, and VEGF signals are the same as in retinas with BSS injection (Fig.  1A) . Thus, intravitreal injection itself does not alter VEGF expression in retina.
No quantitative change of VEGF mRNA level by triamcinolone
Northern blot analysis was performed to confirm that the signals in the in situ hybridization study were VEGF mRNA by checking its molecular weight. Since in situ hybridization is only a semi-quantitative method for signal quantification, but an excellent technique to detect the localization of mRNA signals, northern blot was also utilized to further quantitate and compare VEGF mRNA expression levels between the triamcinolone and BSS control groups using rat VEGF riboprobes (see Section 2). Total RNA was isolated from retinas of eyes treated for three weeks with either intravitreal triamcinolone or BSS. Northern blot revealed a single characteristic band migrating at 4.2 kb corresponding to VEGF mRNA as reported previously (Fig. 3) . This confirms that the signals detected in in situ hybridization and in Northern blot are indeed VEGF mRNA. b-actin mRNA expression was also examined and used as an internal control since b-actin is known to be a housekeeping gene and expressed at a constant level (Oue, Taira, Shima, Miyazaki, & Puri, 1999) . Relative levels of VEGF mRNA were expressed as a ratio of the band density divided by that of b-actin. Densitometry analysis shows no significant difference of VEGF mRNA expression in triamcinolone over that in BSS control groups (p > 0:05) (Fig. 3) . Thus, Northern blot analysis confirms the in situ hybridization results and shows that VEGF mRNA expression level is not changed 3 weeks following intravitreal triamcinolone treatment.
Discussion
In the present study, VEGF mRNA expression was examined in normal adult rat retina. Our in situ results are very comparable with other reports (Yi et al., 1997) demonstrating that VEGF expression is present in the RPE, cells in the INL and ganglion cells (Fig. 1) . VEGF mRNA shows a molecular weight at 4.2 kb in northern blot consistent with prior studies (Gao et al., 2001) . The VEGF positive cells in the INL were proved to be Muller cells in mouse . Only a small portion of ganglion cells expresses VEGF, however, it remains to be determined which specific sub-population of ganglion cells.
The exact effect of steroid on VEGF expression in the retina is still unknown. There is conflicting data in the literature regarding the effect of glucorticoids on VEGF expression. It has been reported that triamcinolone reduces VEGF expression in cultured aortic vascular smooth muscle cells (Nauck, Karakiulakis, Perruchoud, Papakonstantinou, & Roth, 1998) . Glucocorticosteroid also reduces VEGF mRNA and protein expression in cultured eosinophils (Horiuchi & Weller, 1997) . On the other hand, strong evidence exists that steroid has no effect on VEGF expression. By comparing VEGF expression in human hemangioma specimen with and without steroid treatment, Hasan et al. found that triamcinolone injection does not change tissue VEGF expression (Hasan, Tan, Gush, Peters, & Davis, 2000) . In the present study, intravitreal triamcinolone does not show any significant change of VEGF mRNA expression in rat retina three weeks after treatment (Figs. 2 and  3 ). As these results seem to segregate between in vivo and in vitro experiments, the difference could be due to altered environmental conditions. Since basic fibroblast growth factor (bFGF) has also been implicated in the development of neovascularization, bFGF expression has been evaluated with steroid treatment. In cultured choroidal endothelial cells, triamcinolone significantly reduces bFGF expression (Wang, Friedrichs, Eichler, Hoffmann, & Wiedemann, 2002) ; whereas in excised human hemangioma specimen, triamcinolone does not change bFGF expression (Hasan et al., 2000) . It is possible that triamcinolone's effects on cells are determined by environment these cells are located. Experimental results from in vitro studies can not directly be compared with those from in vivo studies.
The mechanisms by which triamcinolone suppresses or inhibits the development of CNV remain unknown. It remains to be determined whether triamcinolone regulates VEGF expression in CNV membrane in exudative AMD or in animal models such as those induced by laser treatments, and whether triamcinolone regulates VEGF expression in the retina and RPE which are adjacent to CNV membrane. It is possible that triamcinolone may inhibit VEGF expression in abnormal or diseased RPE. A recent study showed that when only the RPE over-expressed VEGF, which was induced by a sub-retinal recombinant adenovirus vector expressing VEGF, CNV formed in the adjacent region close to the RPE (Spilsbury, Garrett, Shen, Constable, & Rakoczy, 2000) . Furthermore, the severity and extent of the resulting CNV were affected by controlling the amount of VEGF expression. Others reported that migrating RPE, which are not normally present in the retina, in the CNV membrane expressed VEGF (Spilsbury et al., 2000) . However, in animal model with systemic VEGF over-expression achieved through transgenic mouse techniques, pre-retinal and intra-retinal neovascularization developed, but CNV did not occur (Okamoto et al., 1997) . Thus CNV may be stimulated by focal over-expression of VEGF, at least partly from the diseased RPE. Since triamcinolone inhibits CNV formation (Challa et al., 1998; Ciulla et al., 2001; Danis et al., 1996; Jonas et al., 2003; Penfold et al., 1995; Ranson et al., 2002) , it remains to be determined whether triamcinolone reduces VEGF expression in focal diseased RPE in the area where CNV happens adjacently, whether triamcinolone inhibits RPE migration to the CNV membrane.
It is known that macrophages are present in human CNV membranes, and macrophage accumulation in the sub-retinal space peaks before the development of CNV (Grossniklaus et al., 2002) . Studies show that macrophages can produce VEGF (Ishibashi et al., 1997; Itaya et al., 2001) . Several studies implicate macrophages as the major source of VEGF in the CNV membrane (Grossniklaus et al., 2002; Yi et al., 1997) . Studies of human endometriosis development show similar findings: macrophages are the major source of VEGF in human endometriosis tissues (McLaren et al., 1996) . Since steroid can inhibit macrophage migration (Bucala, 1998) , it is possible that triamcinolone reduces CNV formation through inhibiting macrophage migration to the sub-retinal CNV membrane. Further experiments need to be done to examine whether triamcinolone also suppresses VEGF expression in macrophages.
Development of CNV in human exudative AMD is a complicated process and multiple growth factors may be involved (Frank, Amin, Eliott, Puklin, & Abrams, 1996) . Another angiogenesis factor, bFGF, may also play a role in the development of CNV (Campochiaro, Soloway, Ryan, & Miller, 1999) . It has been reported that triamcinolone inhibited bFGF-induced proliferation of choroidal vascular endothelium in vitro which leads to vessel formation (Wang et al., 2002) . Studies also show that triamcinolone significantly down-regulates intercellular adhesion molecule-1 (ICAM-1) expression and decreases paracellular permeability in cultured epithelium, and thus potentially strengthens the barrier function of the RPE and reduces sub-retinal edema (Penfold et al., 2000) . Triamcinolone also downregulates MHC-II expression and thus reduces inflammatory markers and endothelial cell permeability (Penfold, Wong, Gyory, & Billson, 2001) . Thus triamcinolone may affect multiple factors to inhibit the development of CNV in human AMD.
